Introduction
The Income Tax Appellate Tribunal (ITAT), Ahmedabad Bench ‘D’, delivered a significant ruling in the case of Zydus Hospira Oncology Pvt. Ltd. v. DCIT (ITA Nos. 87/AHD/2022, 1521/AHD/2024, and 2123/AHD/2024), concerning Assessment Years 2017-18, 2020-21, and 2021-22. This case commentary analyzes the Tribunal’s decision, which addressed a complex transfer pricing dispute involving a joint venture and several ancillary corporate tax issues. The bench, comprising Dr. BRR Kumar (Vice President) and Shri Sanjay Kumar (Judicial Member), partly allowed the appeals, upholding the transfer pricing adjustment while providing relief on depreciation, deductions, interest, and penalty proceedings. This decision underscores the judiciary’s nuanced approach to related-party transactions within joint ventures and reaffirms established principles on software depreciation and statutory deductions.
Facts of the Case
The assessee, Zydus Hospira Oncology Pvt. Ltd. (ZHOPL), is a 50:50 joint venture incorporated in 2005 between Cadila Healthcare Limited (CHL) and Mayne Pharma Pty Ltd, which was later taken over by Hospira Australia Pty Limited (HAPL). The core dispute revolved around the License Distribution Agreement (LDA) dated 25.09.2008 with Hospira Enterprises, BV (HEBV), an Associated Enterprise (AE). Under this agreement, ZHOPL manufactured six formulation products at its facility and sold them to HEBV for distribution in specified territories. The pricing mechanism stipulated that ZHOPL would be compensated at “cost + 20% or 50% of net sale value made by HEBV and its affiliates, whichever is higher.” The excess over cost + 20% was termed “true up charges.”
For AY 2017-18, the assessee sold drugs worth Rs. 278.28 Crore to HEBV. The Transfer Pricing Officer (TPO), relying on orders from preceding years, rejected the assessee’s Transfer Pricing Study, which had used the ‘Other Method’ and selected itself as the tested party. Instead, the TPO applied the Profit Split Method (PSM), relying on comparables from AY 2012-13 and allocating profits in a 50:15:35 ratio for manufacturing, R&D, and marketing functions, respectively, based on the Rolls Royce Plc ruling. This resulted in a transfer pricing adjustment of Rs. 16.69 Crore. The assessee challenged this before the Dispute Resolution Panel (DRP), which upheld the TPO’s approach, leading to the appeal before the ITAT.
The assessee raised multiple grounds, including the validity of the assessment order’s limitation, the appropriateness of the PSM, depreciation on software, deduction under Section 10AA, interest under Sections 234A and 234B, MAT credit under Section 115JAA, and penalty proceedings under Section 270A.
Reasoning and Analysis
The ITAT’s reasoning is the cornerstone of this judgment, addressing each ground with detailed legal analysis.
Transfer Pricing Adjustment (Ground 1): The assessee’s primary argument was that the pricing mechanism in the LDA was agreed upon between two unrelated joint venture partners (CHL and HAPL) in the Joint Venture Agreement (JVA) and should therefore be considered at arm’s length. The assessee further contended that the TPO erred in attributing significant rewards to ZHOPL for R&D functions and product IP, and in treating its USFDA-approved manufacturing facility as a significant intangible. It also challenged the application of the PSM, the reliance on stale comparables from AY 2012-13, and the allocation ratio derived from the Rolls Royce Plc case.
The Tribunal rejected these arguments. It held that the pricing mechanism in the JVA, although between two unrelated parties, did not constitute an uncontrolled transaction. The parties had a common interest in the joint venture, and the pricing was not determined in an open market. The Tribunal emphasized that joint venture partners’ common interest prevents their agreement from being treated as an uncontrolled transaction for transfer pricing purposes. It upheld the application of the PSM, noting that the assessee performed manufacturing functions using intangibles, while the AEs performed distribution and marketing functions. The Tribunal found no fault with the TPO’s allocation, which recognized the relative contributions of each party to the value chain. This reasoning aligns with the principle that in a joint venture, the partners act in concert rather than as independent parties negotiating at arm’s length.
Depreciation on Software (Ground 2): The assessee claimed depreciation on software at 60% under Clause III of Appendix I to Rule 5, but the AO allowed only 25%/12.5% as applicable to intangible assets. The Tribunal followed its earlier decisions in the assessee’s own case for AYs 2010-11 and 2011-12 and held that software is eligible for depreciation at 60%. This finding reinforces the consistent judicial view that computer software is a tangible asset eligible for higher depreciation rates.
Deduction under Section 10AA (Ground 3): The assessee claimed a deduction of Rs. 41.22 Crore under Section 10AA, which was not disturbed during assessment proceedings. However, the AO failed to allow it while computing tax payable, resulting in excess tax. The Tribunal held that the deduction, having not been disturbed, should be allowed. This underscores the principle that once a claim is accepted during assessment, it cannot be arbitrarily denied at the tax computation stage.
Interest under Sections 234A and 234B (Grounds 4 and 5): The Tribunal deleted interest under Section 234A of Rs. 13.57 Lakh and under Section 234B of Rs. 8.00 Crore. It noted that the assessee had filed its return within the due date and the tax was paid, making the levy of interest unsustainable. This reaffirms the settled position that interest under these sections is compensatory and cannot be levied when the assessee has complied with statutory obligations.
MAT Credit (Ground 6): The Tribunal allowed MAT credit under Section 115JAA, as claimed by the assessee. This is a straightforward application of the law, ensuring that the assessee receives credit for taxes paid under the Minimum Alternate Tax regime.
Penalty Proceedings under Section 270A (Ground 7): The Tribunal did not sustain the penalty proceedings, as the assessee had disclosed all particulars. This finding is significant as it protects the assessee from penal consequences when there is no concealment or furnishing of inaccurate particulars.
Additional Ground on Limitation: The assessee raised an additional ground challenging the assessment order dated 10.02.2022 as barred by limitation. However, the Tribunal’s order does not explicitly discuss this ground, possibly because it was not pressed or was rendered academic by the other findings.
Conclusion
The ITAT Ahmedabad’s decision in Zydus Hospira Oncology is a balanced ruling that upholds the transfer pricing adjustment under the Profit Split Method while providing substantial relief on other grounds. The Tribunal’s reasoning on the joint venture pricing mechanism is particularly instructive, clarifying that agreements between joint venture partners, even if unrelated, do not automatically qualify as uncontrolled transactions for transfer pricing purposes. The decision also reinforces established principles on software depreciation, statutory deductions, and the levy of interest and penalties. For taxpayers, this judgment serves as a reminder of the importance of robust transfer pricing documentation and the need to align pricing mechanisms with arm’s length principles, especially in joint venture structures. The case is a valuable addition to the jurisprudence on transfer pricing and corporate tax compliance in India.